

## Special Issue

# Epigenomics, Epitranscriptomics and Novel Therapy Approaches in Hematology

### Message from the Guest Editor

We launch this Special Issue with the aim to gain new insights into the epigenomics and epitranscriptomics in normal and malignant hematopoiesis, and to explore novel therapeutic approaches to treat hematological diseases. In this regard, we encourage the submission of research articles or reviews in the field of clinical or experimental hematology on the following topics: 1) gene mutations or polymorphisms impacting on epigenome or epitranscriptome; 2) functional characterization of regulators of epigenome or epitranscriptome; 3) clinical evaluation of epigenome or epitranscriptome in patients; 4) animal models to study altered epigenome or epitranscriptome; 5) novel or improved methodological development to quantify the epigenome or epitranscriptome; 6) novel gene therapies, gene manipulation, small molecules, or drug synergy with potency to tackle hematological disorders; and 7) clinical trials of novel targeted therapy drugs in hematology.

---

### Guest Editor

Dr. Haiyang Yun

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

---

### Deadline for manuscript submissions

closed (15 March 2023)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/si/97914](https://mdpi.com/si/97914)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))